The vaccine is quick and easy to prepare and can be mass-produced in a short period of time to respond to sudden outbreaks
News from our newspaper (reporter Lei Jia, Li Zhuoya) News from the State Intellectual Property Office, the new crown vaccine patent application jointly filed by Academician Chen Wei of the Academy of Military Medical Research of the Academy of Military Sciences and Cansino Bio has been granted patent rights recently. This is China The first new crown vaccine patent.
The State Intellectual Property Office’s notice of granting invention patents stated that the name of the patent was "a recombinant new coronavirus vaccine using human replication-deficient adenovirus as a vector." 15 inventors including Chen Wei, Wu Shipo, Hou Lihua, etc., became my country's first new crown vaccine patent. It is understood that the vaccine is an adenovirus vector vaccine (Ad5-nCoV vaccine) developed by the team of Academician Chen Wei. It was applied for on March 18 this year and was authorized on August 11. Academician Chen Wei, along with Zhang Boli and Zhang Dingyu, was awarded the national honorary title of "People's Hero" on August 11th for making outstanding contributions in the fight against the new crown pneumonia epidemic.
The abstract of the patent states: "The present invention provides a new type of coronavirus vaccine based on human replication-deficient adenovirus type 5... This vaccine has good immunogenicity in both mouse and guinea pig models. It induces the body to produce a strong cellular and humoral immune response in a short time. The protective effect of HACE2 transgenic mice has shown that Ad5-nCoV can significantly reduce the viral load in the lung tissue after 14 days, indicating that the vaccine is effective against 2019 new coronavirus Good immune protection effect. In addition, the vaccine is quick and easy to prepare, and can be produced on a large scale in a short period of time to respond to emergencies.” According to previous reports, the vaccine was the first to enter phase I and phase II clinical trials in China and internationally. , Verified the safety and immunogenicity of the vaccine, and the Phase III international clinical trial is proceeding in an orderly manner.
According to the international authoritative medical journal "The Lancet", there are currently about 250 candidate new coronavirus vaccines in the world, at least 17 of which are in clinical trials.